Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Neutropenia Biologic Drug Treatment Market From 2025 To 2029?

The market for biologic drugs treating neutropenia has significantly expanded in the recent past. The market, valued at $13.22 billion in 2024, is forecasted to increase to $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the growth during the historic period include market accessibility and reimbursement practices, efforts towards patient advocacy and awareness, education and training of physicians, as well as successful biological drug development and clinical trials.

What Is the Projected Market Size of the Neutropenia Biologic Drug Treatment Market?

The market size for biologic drug treatment of neutropenia is projected to experience a significant surge in the coming years. By 2029, the valuation is estimated to reach $18.1 billion, growing at a compound annual growth rate (CAGR) of 6.5%. The predicted growth during the forecast period can be linked to several factors such as the management of healthcare costs, patient-oriented care plans, development of combination therapies, regulatory alterations and approvals, as well as approaches involving personalized medicine. Major trends expected within the forecast period encompass accessibility to the global market, enhancements in manufacturing methods, streamlining of treatment protocols, adoption of biosimilars, and establishment of long-acting formulations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp

Who are the Major Competitors in the Neutropenia Biologic Drug Treatment Market Outlook?

Major companies operating in the neutropenia biologic drug treatment market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Celgene Corporation, Biogen Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Gilead Sciences Inc., Daiichi Sankyo Company, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

What Is Fueling Growth in the Neutropenia Biologic Drug Treatment Market?

The global increase in cancer cases is expected to stimulate the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with more people choosing chemotherapy, has led to a rise in neutropenia sufferers. For example, the American Cancer Society reported in January 2022 that there will likely be 1.9 million fresh cancer cases and 609,360 cancer-related death in the U.S., equating to about 1,670 deaths per day. Lung, prostate, bowel, and female breast cancer, the four most prevalent types globally, represent 43% of all new cancer cases. Consequently, the global uptick in cancer rates is predicted to spur demand for the neutropenia biologic drug treatment market in the near future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3456&type=smp

Which Neutropenia Biologic Drug Treatment Market Segments Are Growing the Fastest?

The neutropenia biologic drug treatment market covered in this report is segmented –

1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim

2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Filgrastim: Brand Name Examples: Neupogen, Indications And Usage

2) By Pegfilgrastim: Brand Name Examples: Neulasta, Indications And Usage

3) By Lenograstim: Brand Name Examples: Granocyte, Indications And Usage

4) By Lipegfilgrastim: Brand Name Examples: Lonquex, Indications And Usage

5) By Sargramostim: Brand Name Examples: Leukine, Indications And Usage

Which Industry Trends Are Shaping the Future of the Neutropenia Biologic Drug Treatment Market?

Leading corporations in the neutropenia biologic drug treatment market are innovating biosimilars as a more affordable alternative to existing biologics. Biosimilars are a type of biologic drug intended to be almost identical to a previously approved biologic drug, with no significant variations in safety or efficacy. For instance, Fylnetra (pegfilgrastim-pbbk), an analogue of Neulasta, was launched by US-based Amneal Pharmaceuticals in May 2023 to prevent and treat febrile neutropenia in chemotherapy patients. It functions by binding to specific receptors on hematopoietic cells and encouraging the growth and differentiation of precursors of neutrophils in the bone marrow. This process boosts the production of neutrophils, vital in fighting infections, particularly in patients subjected to myelosuppressive chemotherapy, hence minimizing the occurrence of febrile neutropenia linked to cancer therapies.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Which Countries Are Leading the Neutropenia Biologic Drug Treatment Market?

The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3456

This Report Delivers Insight On:

1. How big is the neutropenia biologic drug treatment market, and how is it changing globally?

2. Who are the major companies in the neutropenia biologic drug treatment market, and how are they performing?

3. What are the key opportunities and risks in the neutropenia biologic drug treatment market right now?

4. Which products or customer segments are growing the most in the neutropenia biologic drug treatment market?

5. What factors are helping or slowing down the growth of the neutropenia biologic drug treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model